The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa

PHASE4CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

July 3, 2018

Primary Completion Date

January 7, 2020

Study Completion Date

January 7, 2020

Conditions
Parkinson Disease
Interventions
DRUG

Pramipexole SR

Tablets

DRUG

Pramipexole IR

Tablets

Trial Locations (12)

30052

Tianjin Medical University General Hospital, Tianjin

100032

Peking Union Medical College Hospital, Beijing

100730

Beijing Hospital, Beijing

110001

The First Hospital of Chinese Medical University, Shenyang

200025

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

210029

Brain Hospital Affiliated to Nanjing Med University, Nanjing

215004

The Second Affiliated Hospital of Soochow University, Suzhou

310009

2nd Affiliated Hosp Zhejiang University College of Medical, Hangzhou

430022

Wuhan Union Hospital, Wuhan

510080

The First Afiliated Hospital, Sun Yet-sen University, Guangzhou

610041

West China Hospital, Chengdu

710061

First Affiliated Hospital of Xi'an JiaoTong University, Xi'an

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT03521635 - The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa | Biotech Hunter | Biotech Hunter